Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting Roche's (RHHBY) Actemra. Read more here.

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

One of the worst complications of adult-onset Still's disease is macrophage activation syndrome (MAS), which can be fatal. In ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...